Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB–IIA1)

Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer

“…A variety of chemotherapeutic protocols have been used followed by fertility-sparing surgery. The first-line combination of TIP (paclitaxel, Ifosfamide and cisplatin) or TEP (paclitaxel, epirubicin and cisplatin) is currently most often used [7,11,12,14,15]. There are more complete responses, but the interval between chemotherapy normally varies between 21 and 28 days.…”

Neoadjuvant chemotherapy followed by conization to spare fertility in cases of locally advanced cervical cancer: A case report and review of the literature

“…Furthermore, NACT also allows for a possible decrease in the extent of surgery to preserve some cervical tissue to achieve an improved pregnancy outcome. Marchiole et al (15), Tsuji et al (16) and Lanowska et al (17) reported that 28 patients whose tumours were >2 cm or who had chemosensitive bulky disease received NACT, followed by fertility-sparing surgery, which consisted of RT and lymphadenectomy. Of these cases, one developed recurrent disease.…”

Fertility-sparing management of gynecological cancers

“…Several authors published small series of patients diagnosed with bulky tumors of the cervix (FIGO IB > 2 cm up to FIGO IIA1 disease) who underwent conservative surgery after neoadjuvant chemotherapy (NACT) [17][18][19][20]. See Table 1.…”